Objectives. Elevated serum uric acid (SUA) levels have been associated with cardiovascular disease (CVD) in the general population. Rheumatoid arthritis (RA) is not thought to associate with high SUA but is characterized by increased CVD morbidity and mortality. We aimed to explore a potential association of SUA with CVD in RA patients and to evaluate whether such an association is present when the traditional CVD risk factors are taken into account. Methods. 400 consecutive RA patients were recruited in this cross-sectional study and had all traditional CVD risk factors and SUA assessed. The association of SUA levels with other variables was assessed using bivariate correlations. Subsequent binary logistic models with appropriate adjustments were used to test the independence of the association between SUA and CVD. Results. SUA levels were significantly higher in RA patients with CVD (RA þ CVD) compared with RA patients without CVD (RA À CVD) (5.68 AE 1.81 mg dl À1 vs 5.06 AE 1.41 mg dl À1 , P ¼ 0.001). After adjusting for CVD risk factors, physical function (health assessment questionnaire, HAQ) and use of diuretics and/or statins the association between SUA and CVD in RA patients remained significant [Odds ratio (OR) ¼ 1.36, 95% confidence interval (CI) 1.04-1.79, P ¼ 0.025]. Compared with subjects with SUA levels in the lowest quintile (<3.86 mg dl À1 ), those within the highest quintile (!6.38 mg dl À1 ) had a 6-fold increase in the odds of having CVD (adjusted OR 6.46, 95% CI 1.66-25.05, P ¼ 0.007). Conclusions. This cross-sectional study suggests that SUA may be independently associated with CVD in RA patients. This needs to be confirmed in prospective studies.
Introduction
Rheumatoid arthritis (RA) is associated with excess cardiovascular morbidity and mortality [1, 2] . There is growing evidence that cardiovascular disease (CVD) manifested as acute myocardial infarction (MI), sudden death, stroke or heart failure (HF) is highly prevalent in RA [3] . The Nurses Health Study demonstrated that the relative risk of MI in women with RA is twice that of those without RA [2] , after adjusting for physical activity and use of drugs such as corticosteroids and non-steroidal antiinflammatory drugs (NSAIDs). Recent studies [4, 5] showed also a higher risk of unrecognized MIs and sudden death, and a lower likelihood of angina symptoms in RA patients, thus indicating a different pattern of clinical expression of CVD in rheumatoid patients. This pattern may include different pain perception and generalized hyposensitivity to myocardial ischaemia [6] . The increased prevalence and spurious manifestation of CVD disease in RA patients renders the identification of additional CVD risk factors in this disease particularly important.
Conventional reversible CVD risk factors, including hypertension (HT) [7] , smoking [8] , obesity [9] , dyslipidaemia [10] and insulin resistance [11] are more frequently encountered among RA patients than in the general population, but the CVD burden in RA cannot be fully explained by this. Therefore, non-traditional risk factors such as chronic inflammation have been implicated in the increased CV burden of RA patients [12] .
Uric acid is a metabolic product of purine metabolism that may function as an antioxidant [13] , thus protecting the vasculature from reactive oxygen species (ROS). However, it can also be a mediator of endothelial dysfunction, vascular smooth cell proliferation and low-grade inflammation, all precursors of HT and CVD [14] . Therefore, it is possible that SUA may contribute to, rather than protect against, the development of CVD. Recent evidence demonstrates that SUA is linked to CVD in the general population [14] , but it remains controversial whether this association is independent of other risk factors [15, 16] .
RA is not traditionally associated with hyperuricaemia [17] . Patients with concomitant gout and RA are only rarely encountered and often reported as interesting cases in the literature [18] . It is not surprising, therefore, that with the exception of a single study [19] , the potential association of SUA levels with CVD in RA has not been investigated in any detail. In the present study, we aimed to explore a potential association of UA with CVD in patients with RA and to evaluate whether such an association is independent or mediated through traditional CVD risk factors. Furthermore, we wanted to estimate in this population at what levels SUA appears to exert deleterious effects on the cardiovascular system.
Patient recruitment and characteristics
400 consecutive patients with RA meeting retrospective application of the 1987 revised ACR criteria [20] , attending routine outpatient clinics at the Department of Rheumatology of the Dudley Group of Hospitals, UK, were enrolled in this cross-sectional, one-centre study. The study had local Research Ethics Committee and Research and Development approval and all participants gave their written informed consent according to the Declaration of Helsinki. Basic demographics and clinical characteristics of the study population are shown in Table 1 .
Clinical assessments
All participants underwent a thorough baseline evaluation including a detailed review of their medical history and hospital records, physical examination and contemporary assessments of height, weight, body mass index (BMI), body composition (using the TANITA Body Composition Analyzer BC-418), current disease activity score (DAS28) [21] and physical function using the Health Assessment Questionnaire (HAQ) [22] . All medications were recorded in detail, including low-dose aspirin, anti-hypertensives and oral daily prednisolone. Blood pressure (BP) was the mean of three measurements taken from the right arm with an appropriately sized cuff using a Criticare 506DXN machine (Systems Inc) with the patient seated. The presence of HT was defined as a systolic BP ! 140 mmHg and/or diastolic BP ! 90 mmHg and/or the use of anti-hypertensive medications according to the British Hypertension Society/NICE guidelines [23, 24] . RA patients were classified as having CVD (RA þ CVD) if they had a positive history of any of the following: MI, stroke or transient ischaemic attack (TIA), peripheral vascular disease (PVD), angioplasty, coronary artery bypass grafting (CABG) or if they had a positive Rose questionnaire [25] on assessment. Patients were defined as being diabetic when fasting serum glucose levels were >7 mmol/l and/or oral hypoglycaemic medication or insulin was used. Number of pack-years of smoking was recorded and patients were separated in three different groups: current smokers, ex-smokers and never smoked. Alcohol consumption was recorded as number of units consumed per week in those patients who admitted to drinking more than the maximum recommended weekly levels of 21 and 14 units for males and females, respectively.
Laboratory determinations
Venous blood was collected in the fasting state on the same day and a wide range of tests were performed. All biochemical tests were carried out in the Biochemistry Laboratory of Russells Hall Hospital, Dudley Group of Hospitals NHS Trust, UK. Blood samples were drawn for routine biochemistry in Z Serumsep, Clot Activator Vacuette Õ tubes, greiner bio-one. Samples were spun at 4500g for 5 min and the serum pipetted out for further testing. Routine tests were carried out on the same day and serum for insulin was frozen at À408C until assay. Uric acid, total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides (TGs) and glucose were measured using the Vitros Õ 5, 1 FS chemistry system (www.orthoclinical.com). (SUA is reported in mg dl
À1
; to convert SUA levels from mg dl À1 to mol l -1 multiply by 59. 48.) Renal function was assessed by estimated glomerular filtration rate (GFR) using the six- Homeostasis Model Assessment of Insulin Resistance (HOMA IR) [27] and the Quantitative Insulin sensitivity Check Index (QUICKI) [28] .
Statistical analysis
The Kolmogorov-Smirnov test was used to evaluate whether each parameter followed a Gaussian distribution. All values are expressed as mean AE standard deviation (S.
Pearson correlation and Spearman rho coefficients were used to describe the bivariate relationship of SUA with other parameters.
Univariate and multivariate logistic regression analysis controlling for age, sex, uric acid, hypertension status, number of smoking pack-years, total cholesterol, QUICKI, BMI, HAQ, use of diuretic and use of statin, was utilized to identify the independence of the association of SUA with CVD in RA patients.
Significance was set at a value of P < 0.05. All analyses were carried out using SPSS 13.0 (SPSS Inc, Chicago, IL, USA).
Results
Of the total of 400 patients, 108 (27%) were men and 292 (73%) were women. The mean age was 61.55 AE 12.02 years. The cohort consisted almost exclusively (96%) of Caucasians (reflecting the local demographic split). Most patients (87.5%) were on diseasemodifying anti-rheumatic drugs (DMARDs), with the most widely used (56.3%) being methotrexate (MTX). Only eight (2%) of the total number of patients assessed in this study admitted to drinking more than the recommended maximum weekly levels of 21 and 14 units for males and females, respectively; none of them were hyperuricaemic, their uric acid levels were not significantly different to the rest of the population and they were not over-represented in the RA AE CVD or RA À CVD groups. Due to this, alcohol intake was not included as a factor in the subsequent analysis.
Mean SUA levels were 5.18 mg dl À1 (range 2.1-13.13 mg dl À1 ); 37 (9.3%) patients (6 men and 31 women) were hyperuricaemic as defined by UA levels >8. 41 , P < 0.001). CVD was significantly more prevalent in those within the highest SUA quintile (!6.38 mg dl
À1
) compared with those in the lowest SUA quintile (<3.86 mg dl À1 ), (34.2% vs 13.9%, P ¼ 0.003). Patients with RA þ CVD had a higher CVD risk factor load compared with patients with RA À CVD (Table 1) : they had a higher prevalence of hypertension (85.9 vs 67.8%, P ¼ 0.002), were heavier smokers (10.0 vs 2.75 pack-years, P ¼ 0.032) and were more prone to be insulin resistant as reflected by HOMA IR (2.76 vs 1.79, P < 0.001) or QUICKI (0.33 vs 0.35, P < 0.001). Physical function was worse (HAQ 2.0 vs 1.375, P < 0.001) and extraarticular features more common (78.2 vs 64.6%, P ¼ 0.022) in RA þ CVD compared with RA À CVD.
In bivariate analysis, SUA levels correlated significantly with TGs ( ¼ 0.24, P < 0. SUA levels were associated with the likelihood of having CVD both before and after adjustment for all possible confounders arising from the above bivariate correlations. In logistic regression (Table 2 ) with dependent variable the presence of CVD, crude OR was 1.29/1 mg dl À1 SUA increase (95% CI 1.1-1.52, P ¼ 0.002). After adjusting for age, gender, HT, BMI, Total Cholesterol, smoking pack-years, QUICKI, HAQ, RA disease duration, use of diuretics and statins, the association between SUA and CVD in RA patients remained significant (OR ¼ 1.36, 95% CI 1.039-1.79, P ¼ 0.025). The adjusted Nagelkerke R 2 of the model was 0.48. Compared with subjects with SUA levels in the lowest quintile, those within the highest quintile had a 3.21-time increase in the odds of having CVD (95% CI 1.46-7.06, P ¼ 0.004; Table 3 ). This association also remained strong after adjustment for potential confounders (OR 6.46, 95% CI 1.66-25.05, P ¼ 0.007).
Discussion
In this cross-sectional observational study, SUA levels were found to be associated with the presence of CVD in RA patients. This association remained significant even after adjustment for traditional CVD risk factors such as hypertension, smoking pack-years, total cholesterol, obesity and insulin resistance indices, as well as other potential confounders, such as renal function, use of drugs and RA disease severity, suggesting that SUA may be independently associated with CVD. This was further reinforced by the finding that RA patients within the highest SUA quintile were six times more likely to have CVD, compared with those within the lowest SUA quintile (OR 6.46, 95% CI 1.66-25.05, P ¼ 0.007). The cross-sectional, observational character of the present study is an obvious limitation: it cannot provide proof of causality or independence in the associations found and any interpretations can only be made with caution. It can, however, serve for hypothesis-generation, which can be further investigated in prospective studies designed specifically for the purpose. Another possible limitation of our study could be the lack of detailed data on alcohol consumption.
In the general population, the relationship between elevated SUA levels and the presence of, risk for, or death from CVD has been extensively investigated. In many studies, the significant association between SUA and CVD has been lost after adjusting for classical CVD risk factors [16, [29] [30] [31] [32] . In others the significant independent association of SUA and CVD applied only to women [33] , whereas in some [15, 34, 35] , the significance was retained even after adjustment for potential confounders. The National Health and Nutrition Examination Survey [15] , a national US observational study on 5926 subjects, suggested that uric acid is an independent, significant factor for CVD, even after adjustment for the traditional risk factors, age, race and use of diuretics. This association and its potentially significant implications obviously remain somewhat controversial; reasons for these discrepancies include important differences in study designs, populations and outcomes assessed.
In our study, SUA levels showed significant bivariate associations with several classical risk factors, including HT and metabolic factors, such as dyslipidaemia and insulin resistance. HT is highly prevalent in RA patients [7, 36] , and may be a strong indirect link between SUA and CVD: induced mild hyperuricemia in rats has been shown to cause hypertension and salt sensitivity [37] , while in humans, many studies have shown the relationship between SUA and HT [38, 39] . New onset essential HT in adolescents is also associated with an elevated UA (UA > 5.5 mg/dl) in the vast majority (90%) of cases, whereas it is present only in 30% of subjects with secondary HT and is rare in white-coat and normotensive adolescents [40] . In the present RA cohort, SUA correlated also with a variety of metabolic abnormalities, such as lipids and insulin resistance indices, which, together with hypertension, constitute the basic components of the metabolic syndrome. Recent studies demonstrate an increased prevalence of the metabolic syndrome in RA [41] , and it has been proposed that hyperinsulinaemia stimulates UA reabsorption in the proximal tubule [42] . It is, therefore, possible that SUA, even within the normal range, serves as a surrogate marker of the dysmetabolic state associated with the metabolic syndrome, and may be marking out RA patients with increased CVD risk. Indeed, in the general population, Short et al. [43] . demonstrated that SUA levels above 5.2 mg/dl were associated with 3.5-fold increased odds (OR ¼ 3.5, 95% CI 1.0-11.9) for CV death and major clinical events in high-risk patients with prevalent coronary artery disease. This result is mirrored closely in our study in those RA patients who were within the highest SUA quintile (!6.8 mg/dl).
In the present study, however, as in some of the general population studies, SUA appeared to have an independent association with the presence of CVD, after correction for most of the above factors. SUA has been suggested to be able to lead directly to CVD, by causing endothelial dysfunction and lowgrade inflammation [44] . A recent study from Khosla et al. [45] has shown a decreased serum nitric oxide in hyperuricaemic rats, which is reversible by lowering SUA levels using allopurinol. In the same study, SUA impaired nitric oxide generation in cultured endothelial cells, implying that hyperuricaemia induces endothelial dysfunction, the beginning of the cardiovascular continuum [46] . After urate uptake into human vascular smooth cells there is a rapid phosporylation of the ERK1/2 and MAP kinases followed by the activation of the nuclear transcription factors NF-kB and AP-1 [47] . Transcription factor activation can lead to increased expression of cyclo-oxygenase-2 (COX-2) and thromboxane A2 (TXA2) [48] . Increased TXA2 may then lead to the production of platelet-derived growth factor (PDGF) and monocyte chemoattractant protein-1 (MCP-1), which can induce smooth muscle proliferation and monocyte/macrophage infiltration, respectively. MCP-1 is one of the central chemokines involved in vascular disease and atherosclerosis [49] . SUA can also stimulate human mononuclear cells to produce interleukin-1, interleukin-6 and tumour necrosis factor-(TNF-) [50] , all of which have a wellestablished contribution to the pathways leading to vascular disease [51] . These may be collectively reflected in the levels of the acute-phase protein CRP, which has emerged as an important predictor of MI, stroke and vascular death [52] . Stimulation by UA leads in vitro to significantly increased CRP production in human vascular cells, providing a possible link between elevated SUA and CRP (and the systemic inflammatory response) in patients with CVD.
In conclusion, this study has demonstrated a potential independent association between SUA levels and CVD in patients with RA. The possible pathogenic mechanisms and potential clinical use of SUA as an early biomarker of future CVD events in this group of patients needs to be further investigated in prospective studies.
